“We deeply sympathize with the women and families impacted by ovarian cancer. The jury’s decision is consistent with the science, research, clinical evidence and decades of studies by medical experts around the world that continue to support the safety of cosmetic talc. This verdict is in addition to the dismissal of two cases in New Jersey in September 2016 by a state court judge who ruled that plaintiffs’ scientific experts could not adequately support their theories that talcum powder causes ovarian cancer, a decision that highlights the lack of credible scientific evidence behind plaintiffs’ allegations. We are preparing for additional trials this year in St. Louis and other U.S. cities and we will continue to defend the safety of Johnson’s Baby Powder.” - Carol Goodrich, Global Media Relations, Johnson & Johnson Consumer, Inc.
